Amgen Inc. (NASDAQ:AMGN) belonging to the Medical sector has declined -0.57% and closed its last trading session at $166.58.
The company reported its EPS on 02/02/2017. Currently, the stock has a 1 Year Price Target of $182.88.
The consensus recommendation, according to Zacks Investment research, is 2.16. The scale runs from 1 to 5 with 1 recommending Strong Buy and 5 recommending a Strong Sell. The Stock had a 2.32 Consensus Analyst Recommendation 30 Days Ago, whereas 60 days ago and 90 days ago the analyst recommendations were 2.41 and 2.41 respectively.
Amgen Inc. on 02/02/2017 reported its EPS as $2.89 with the analysts projecting the EPS of the stock as $2.79. The company beat the analyst EPS Estimate with the difference of $0.1. This shows a surprise factor of 3.6%.
Many analysts have provided their estimated foresights on Amgen Inc. Earnings, with 17 analysts believing the company would generate an Average Estimate of $2.99. Whereas they predicted High and Low Earnings Estimate as $3.19 and $2.8 respectively. While in the same Quarter Previous year, the Actual EPS was $2.9.
Analysts are also projecting an Average Revenue Estimate for Amgen Inc. as $5.59 Billion in the Current Quarter. This estimate is provided by 13 analysts. The High Revenue estimate is predicted as 5.8 Billion, while the Low Revenue Estimate prediction stands at 5.32 Billion. The company’s last year sales total was 5.53 Billion.
For the Current Quarter, the growth estimate for Amgen Inc. is 3.1%, while for the Next Quarter the stock growth estimate is 9.5%. In the past 5 years, the stock showed growth of 17.15% per annum. While for the next 5 years, the growth estimate is 6.77%.
The Company got Upgrade by BofA/Merrill on 1-Feb-17 from Neutral to Buy.
Insider Trades for Amgen Inc. show that the latest trade was made on 30 Jan 2017 where Harper (Sean E), the Officer completed a transaction type “Sell” in which 668 shares were traded at a price of $154.43.
Over the period of 6 months, Insider Purchases show a total of 1 transaction in which 3010 shares were traded. 6 Insider Sales transactions were made totaling 67327 shares traded.
20 analysts projected Price Targets for Amgen Inc.. The analysts believe that the company stock price could grow as high as $209. The Low Price target projection by analysts is $158.51 and the Mean Price Target is $182.88.
Amgen Inc. (NASDAQ:AMGN) has the market capitalization of $123.6 Billion. The company rocked its 52-Week High of $176.85 on Sep 23, 2016 and touched its 52-Week Low of $133.64 on Nov 4, 2016. The stock has Return on Assets (ROA) of 10.1 percent. Return on Equity (ROE) stands at 25.9% and Return on Investment (ROI) of 13 percent.
The stock is currently showing YTD performance of 13.93 Percent. The company has Beta Value of 1.19 and ATR value of 3.31. The Weekly and Monthly Volatility stands at 1.80% and 1.79%.
Amgen Inc. discovers, develops and delivers innovative human therapeutics. A biotechnology pioneer, Amgen was one of the first companies to realize the new science’s promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people’s lives.